BiondVax Pharmaceuticals (SCNI) - Long-Term Debt to Capital Coefficient

Scinai Immunotherapeutics specializes in developing antibodies for the therapy of skin inflammation, targeting individuals with psoriasis within the extensive chronic dermatology market. This price chart (separate_debt_long_eq) illustrates the asset's dynamics, where the current value is 0.28. Production capacities are based on automated bioreactors that minimize manual labor during the synthesis of complex proteins, ensuring high precision and process safety.

This ratio measures the proportion of liabilities with a maturity exceeding one year relative to equity. For Scinai Immunotherapeutics (SCNI), this metric is critical due to the absence of revenue and high R&D expenditures. By analyzing the current long-term debt-to-equity ratio, an investor assesses the sustainability of the financing structure. A decrease in this value minimizes bankruptcy risks in the event of failed clinical trials. A growing gap between debt and equity signals critical financial pressure.